Peak Bio, Inc. (PKBO) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
4900 HOPYARD ROAD, SUITE 100 PLEASANTON, CA 94588 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 382 | 655 | 329 | |||
| Cash and cash equivalent | 382 | 655 | 329 | |||
| Receivables | 75 | |||||
| Prepaid expense | 1,917 | 2,563 | 71 | |||
| Derivative instruments and hedges, assets | 13 | |||||
| Other undisclosed current assets | ||||||
| Total current assets: | 2,374 | 3,231 | 401 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 3,681 | |||||
| Property, plant and equipment | 153 | 377 | ||||
| Asset, held-in-trust | 57,506 | |||||
| Restricted cash and investments | 60 | 240 | ||||
| Other noncurrent assets | 9 | 2 | ||||
| Total noncurrent assets: | 222 | 4,299 | 57,506 | |||
| TOTAL ASSETS: | 2,596 | 7,530 | 57,907 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 9,439 | 5,656 | 326 | |||
| Accounts payable | 5,862 | 3,618 | ||||
| Accrued liabilities | 3,577 | 2,038 | 326 | |||
| Debt | 1,375 | |||||
| Derivative instruments and hedges, liabilities | 362 | 166 | ||||
| Due to related parties | ✕ | ✕ | 1,962 | 112 | ||
| Other undisclosed current liabilities | 10,722 | 1,642 | ||||
| Total current liabilities: | 20,523 | 10,801 | 438 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 791 | 4,823 | 1,975 | |||
| Accounts payable and accrued liabilities | 560 | |||||
| Other liabilities | 231 | 791 | ||||
| Operating lease, liability | 3,507 | |||||
| Derivative instruments and hedges, liabilities | 525 | 1,975 | ||||
| Other undisclosed noncurrent liabilities | (560) | |||||
| Total noncurrent liabilities: | 231 | 4,823 | 1,975 | |||
| Total liabilities: | 20,753 | 15,624 | 2,413 | |||
| Equity | ||||||
| Equity, attributable to parent | (18,157) | (8,094) | (2,006) | |||
| Common stock | 2 | 2 | 0 | |||
| Additional paid in capital | 19,919 | 17,220 | ||||
| Accumulated other comprehensive income | 94 | 30 | ||||
| Accumulated deficit | (38,171) | (25,346) | (2,006) | |||
| Other undisclosed equity | 57,500 | |||||
| Total equity: | (18,157) | (8,094) | 55,494 | |||
| TOTAL LIABILITIES AND EQUITY: | 2,596 | 7,530 | 57,907 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 368 | 608 | 481 | ||
| Other income | 481 | ||||
| Gross profit: | 368 | 608 | 481 | ||
| Operating expenses | (13,433) | (12,456) | (969) | ||
| Other undisclosed operating loss | (481) | ||||
| Operating loss: | (13,066) | (11,848) | (969) | ||
| Nonoperating income (expense) | 240 | (1,315) | 475 | ||
| Investment income, nonoperating | 837 | 475 | |||
| Other nonoperating income | 46 | 368 | |||
| Interest and debt expense | (2,744) | (467) | |||
| Loss from continuing operations before equity method investments, income taxes: | (15,570) | (13,630) | (494) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 2,744 | 467 | |||
| Loss from continuing operations before income taxes: | (12,826) | (13,163) | (494) | ||
| Income tax expense (benefit) | (16,297) | 74 | |||
| Other undisclosed loss from continuing operations | |||||
| Loss from continuing operations: | (29,123) | (13,089) | (494) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (494) | |
| Other undisclosed net income | 16,297 | ||||
| Net loss: | (12,826) | (13,089) | (494) | ||
| Other undisclosed net income attributable to parent | 6 | ||||
| Net loss available to common stockholders, diluted: | (12,826) | (13,089) | (488) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (12,826) | (13,089) | (494) | ||
| Other comprehensive income (loss) | 64 | (59) | |||
| Other undisclosed comprehensive income | |||||
| Comprehensive loss: | (12,762) | (13,148) | (494) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | |||||
| Comprehensive loss, net of tax, attributable to parent: | (12,762) | (13,148) | (494) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.